Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID)

Clinical Trial ID NCT00494715

Rank	Title	Journal	Year	PubWeight™‹?›
1	The RAAS in the pathogenesis and treatment of diabetic nephropathy.	Nat Rev Nephrol	2010	1.65
2	Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.	Am J Nephrol	2010	1.33
3	Proteinuria: Is the ONTARGET renal substudy actually off target?	Nat Rev Nephrol	2009	0.91
4	Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function.	Ther Adv Drug Saf	2015	0.87
5	Is there added value to adding ARB to ACE inhibitors in the management of CKD?	J Am Soc Nephrol	2008	0.85
6	Application of direct renin inhibition to chronic kidney disease.	Cardiovasc Drugs Ther	2010	0.84
7	Combining angiotensin receptor blockers with ACE inhibitors in elderly patients.	Am J Kidney Dis	2011	0.75
8	Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.	High Blood Press Cardiovasc Prev	2013	0.75
9	The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease.	Rambam Maimonides Med J	2015	0.75